Cover Image
市場調查報告書

癌症生物標記市場:各分析技術(組學技術、影像技術、免疫檢測、細胞遺傳學的檢驗)、各純粹分子、各癌症類型、各用途 - 全球機會分析與產業預測

Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022

出版商 Allied Market Research 商品編碼 421141
出版日期 內容資訊 英文 172 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症生物標記市場:各分析技術(組學技術、影像技術、免疫檢測、細胞遺傳學的檢驗)、各純粹分子、各癌症類型、各用途 - 全球機會分析與產業預測 Cancer Biomarkers Market by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022
出版日期: 2016年12月01日 內容資訊: 英文 172 Pages
簡介

本報告提供全球癌症生物標記市場相關調查,市場趨勢與課題,各分析技術、各純粹分子、各癌症類型、各用途及各地區的趨勢,主要供應商簡介等彙整資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 生物標記診斷和傳統的診斷
  • 主要調查結果
    • 促進要素
    • 阻礙要素
  • 波特五力分析
  • 主要企業的定位
  • 專利分析
  • 臨床實驗

第4章 各分析技術市場

  • 概要
  • 組學技術
  • 影像技術
  • 免疫檢測
  • 細胞遺傳學的檢驗

第5章 各純粹分子市場

  • 概要
  • 遺傳基因生物標記
  • 蛋白質生物標記
  • 格力高生物標記

第6章 各癌症類型市場

  • 概要
  • 肺癌
  • 乳癌
  • 大腸癌
  • 前列腺癌
  • 胃癌
  • 其他

第7章 各用途市場

  • 概要
  • 診斷
  • 藥物研發、開發
  • 預後
  • 風險評估
  • 其他

第8章 各地區市場區隔

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美

第9章 企業簡介

  • Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Qiagen N.V.
  • Genomic Health, Inc.

圖表

目錄

Cancer biomarkers are biomolecules that specifies the existence of cancer or cancerous cells in the body. These are generally molecules that are released due to the presence of a tumor or a particular indication in the body to the presence of cancer. These molecules are densely distributed in tissues, urine, serum, blood, and other body fluids. Their expression levels serve as the basis or indication of any abnormal process or a disease.

The market size of the global cancer biomarkers market was valued at $6,521 million in 2015 and is estimated to grow at a CAGR of 13% over the forecast period to reach $15,737 million in 2022. Market growth is attributed to the increasing incidences of cancers such as lung cancer, breast cancer, and prostate cancer among others coupled with growing importance of biological and targeted drug therapies and technological advancements in the field of cancer treatment. However, unregulated government laws and reimbursement policies; as well as high cost of drug development and threat of failure are anticipated to have an adverse effect on the market growth. Nevertheless, advancement in cancer drugs research and significant unmet need in cancer diagnosis are estimated to overshadow these restraints.

The global cancer biomarkers market is segmented based on profiling technology, biomolecules, cancer type, application, and geography. By profiling technology, the market is segmented into omic technologies, imaging technologies, immunoassays and cytogenetics based tests. Based on biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glycoprotein biomarkers. Amongst these, genetic biomarkers are widely used in the market owing to better diagnostic and therapeutic usage as compared to protein and glycoprotein biomarkers.

The various cancer types include breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Amongst these, lung cancer is the major cancer type where biomarkers are being used for detection. Owing to high tobacco consumption and smoking, lung cancer has increased at an alarming rate. CEACAM-5/CD66e, Cytokeratin 19, EGF R/ErbB1, Enolase 2/Neuron-specific Enolase, Lactate Dehydrogenase A/LDHA, Lactate Dehydrogenase B/LDHB, Napsin A and PDGFRL are some of the major cancer biomarkers used for lung cancer detection.

Geographically, North America is the leading revenue generating region, due to high incidence rate of cancer, growth in awareness towards cancer and higher cancer biomarker testing. Asia-Pacific is growing at the fastest CAGR due to rise in awareness, increased disposable income, and affordability for advanced cancer treatments.

Companies have adopted collaboration and partnership as their key development strategies. Increase in focus on collaboration and partnership is mainly for the development of innovative technologies in the field of cancer biomarkers. In May 2016, Roche received an approval by FDA for its first anti-PD-L1 cancer immunotherapy namely Tecentriq (atezolizumab), thereby expanding its product portfolio.

KEY BENEFITS FOR STAKEHOLDERS:

  • The drivers, restraints, and opportunities in the global cancer biomarkers market are expected to help in understanding the market behavior better.
  • The market estimations are a result of high-end analysis of the key market segments for the period of 2014-2022
  • Projections in the report are made by analyzing the current market trends and future market potential for the forecast period in terms of value. The analysis helps in understanding the strategies adopted by various companies for the growth of the global cancer biomarkers market.
  • Country level analysis has been done to provide micro market sizing of cancer biomarkers in different regions
  • Porter's five forces model gives an in-depth analysis of bargaining power of buyers and suppliers, threats of new entrants & substitutes, and competition amongst the key market players.

KEY MARKET SEGMENTS:

By Profiling Technology

  • Omic Technologies
  • Imaging Technologies
  • Immunoassays
  • Cytogenetics Based Tests

By Biomolecules

  • Genetic Biomarkers
  • Protein Biomarkers
  • Glycoprotein Biomarkers

By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Other Cancers

By Application

  • Diagnostics
  • Drug Discovery and Development
  • Prognostics
  • Risk Assessment
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Biomarker diagnosis vs. conventional diagnosis
  • 3.3. Key findings
    • 3.3.1. Drivers
      • 3.3.1.1. Rise in incidence and prevalence of various cancer types
      • 3.3.1.2. Growth in importance of biological and targeted drug therapies
      • 3.3.1.3. Expiration of key patents and biosimilars impact
      • 3.3.1.4. Increase in acquisitions and collaborations
      • 3.3.1.5. Technological advancements
      • 3.3.1.6. Accuracy and reliability
      • 3.3.1.7. Rise in investment from government, public, and private sectors
      • 3.3.1.8. Increase in clinical trials
      • 3.3.1.9. Growth in popularity of personalized medicine and companion diagnostics
    • 3.3.2. Restraints
      • 3.3.2.1. High cost of drug development and threat of failure
      • 3.3.2.2. Unregulated government regulation and reimbursement policies
      • 3.3.2.3. Adverse effects of cancer drug therapy
      • 3.3.3. Opportunities
      • 3.3.3.1. Advancement of cancer drugs research
      • 3.3.3.2. Increased focus towards advanced treatment protocols
      • 3.3.3.3. Significant unmet need in cancer diagnosis
      • 3.3.3.4. Increased awareness to reduce healthcare costs
      • 3.3.3.5. Opportunities in emerging economies
    • 3.3.4. Top investment pockets
    • 3.3.5. Top winning strategies
  • 3.4. Porters five forces analysis
    • 3.4.1. High bargaining power of suppliers
    • 3.4.2. Low bargaining power of buyers
    • 3.4.3. High threat from substitutes
    • 3.4.4. Low threat of new entrants
    • 3.4.5. High intensity of competitive rivalry
  • 3.5. Top player positioning, 2015
  • 3.6. Patent analysis
    • 3.6.1. U.S. patent analysis by market participant
    • 3.6.2. Europe patent analysis by market participant
    • 3.6.3. China patent analysis by market participant
    • 3.6.4. Canada patent analysis by market participant
    • 3.6.5. Japan patent analysis by market participant
    • 3.6.6. Other countries patent analysis by market participant
  • 3.7. Clinical trials

CHAPTER 4: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.1. Omic technologies
    • 4.1.1. Key market trends
    • 4.1.2. Key growth factors and opportunities
    • 4.1.3. Market size and forecast
    • 4.1.4. Genomics
      • 4.1.4.1. Market size and forecast
      • 4.1.4.2. Next-generation sequencing (NGS)
      • 4.1.4.3. Microarray
      • 4.1.4.4. Polymerase chain reaction (PCR)
    • 4.1.5. Proteomics
      • 4.1.5.1. Market size and forecast
      • 4.1.5.2. Mass spectrometry
      • 4.1.5.3D gel electrophoresis
      • 4.1.5.4. Protein microarray technology
      • 4.1.5.5. Antibody array technology
      • 4.1.5.6. Peptide array technology
    • 4.1.6. Other omic technologies
      • 4.1.6.1. Market size and forecast
      • 4.1.6.2. Metabolomics
      • 4.1.6.3. Glycomics
  • 4.2. Imaging technologies
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
    • 4.2.4. Magnetic resonance imaging
    • 4.2.5. Positron emission tomography
    • 4.2.6. Computed tomography
    • 4.2.7. Mammography
    • 4.2.8. Ultrasound
  • 4.3. Immunoassays
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
    • 4.3.4. Immunohistochemistry tests
    • 4.3.5. Enzyme-linked immunosorbent assay
    • 4.3.6. Flow cytometry
  • 4.4. Cytogenetics-based tests
    • 4.4.1. Key market trends
    • 4.4.2. Key growth factors and opportunities
    • 4.4.3. Market size and forecast
    • 4.4.4. In situ hybridization
    • 4.4.5. Others (karyotyping, amplichip, and in vitro diagnostic multivariate index assays [IVDMIA])

CHAPTER 5: GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE (2014-2022)

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Genetic biomarkers
    • 5.2.1. Market size and forecast
  • 5.3. Protein biomarkers
    • 5.3.1. Market size and forecast
  • 5.4. Glyco-biomarkers
    • 5.4.1. Market size and forecast

CHAPTER 6: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Lung cancer
    • 6.2.1. Market size and forecast
  • 6.3. Breast cancer
    • 6.3.1. Market size and forecast
  • 6.4. Colorectal cancer
    • 6.4.1. Market size and forecast
  • 6.5. Prostate cancer
    • 6.5.1. Market size and forecast
  • 6.1. Stomach cancer
    • 6.1.1. Market size and forecast
  • 6.2. Others
    • 6.2.1. Market size and forecast

CHAPTER 7: CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Diagnostics
    • 7.2.1. Market size and forecast
  • 7.3. Drug discovery and development
    • 7.3.1. Market size and forecast
  • 7.4. Prognostics
    • 7.4.1. Market size and forecast
  • 7.5. Risk assessment
    • 7.5.1. Market size and forecast
  • 7.6. Others (personalized medicine, surrogate endpoints, recurrence, and therapeutics)
    • 7.6.1. Market size and forecast

CHAPTER 8: CANCER BIOMARKERS MARKET BY GEOGRAPHY, 2014-2022

  • 8.1. Overview
    • 8.1.1. Market size and forecast
  • 8.2. North America
    • 8.2.1. Key market trends
    • 8.2.2. Growth factors and opportunities
    • 8.2.3. Market size and forecast
      • 8.2.3.1. U.S.: market size and forecast
      • 8.2.3.2. Canada: market size and forecast
      • 8.2.3.3. Mexico: market size and forecast
  • 8.3. Europe
    • 8.3.1. Key market trends
    • 8.3.2. Growth factors and opportunities
    • 8.3.3. Market size and forecast
      • 8.3.3.1. Germany: market size and forecast
      • 8.3.3.2. UK: market size and forecast
      • 8.3.3.3. France: market size and forecast
      • 8.3.3.4. Italy: market size and forecast
      • 8.3.3.5. Russia: market size and forecast
      • 8.3.3.6. Rest of Europe: market size and forecast
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends
    • 8.4.2. Key growth factors and opportunities
    • 8.4.3. Market size and forecast
      • 8.4.3.1. Japan: market size and forecast
      • 8.4.3.2. China: market size and forecast
      • 8.4.3.3. India: market size and forecast
      • 8.4.3.4. Australia: market size and forecast
      • 8.4.3.5. Rest of Asia-Pacific: market size and forecast
  • 8.5. LAMEA (Latin America, Middle East, and Africa)
    • 8.5.1. Key market trends
    • 8.5.2. Key growth factors and opportunities
      • 8.5.2.1. Brazil: market size and forecast
      • 8.5.2.2. Saudi Arabia: market size and forecast
      • 8.5.2.3. UAE: market size and forecast
      • 8.5.2.4. Rest of LAMEA: market size and forecast

CHAPTER 9: COMPANY PROFILES

  • 9.1. F. Hoffmann-La Roche Ltd.
    • 9.1.1. Company overview
    • 9.1.2. Business performance
    • 9.1.3. Key strategies and developments
  • 9.2. Abbott Laboratories
    • 9.2.1. Company overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Operating business segments
    • 9.2.4. Business performance
    • 9.2.5. Key strategies & developments
  • 9.3. GlaxoSmithKline plc
    • 9.3.1. Company overview
    • 9.3.2. Operating business segments
    • 9.3.3. Business performance
    • 9.3.4. Key strategies and developments
  • 9.4. Novartis AG
    • 9.4.1. Company overview
    • 9.4.2. Operating business segments
    • 9.4.3. Business performance
    • 9.4.4. Key strategies and developments
  • 9.5. Merck & Co., Inc.
    • 9.5.1. Company overview
    • 9.5.2. Company snapshot
    • 9.5.3. Operating business segments
    • 9.5.4. Business performance
    • 9.5.5. Key strategies and developments
  • 9.6. Bristol-Myers Squibb
    • 9.6.1. Company overview
    • 9.6.2. Company snapshot
    • 9.6.3. Business performance
    • 9.6.4. Key strategies and developments
  • 9.7. Eli Lilly and Company
    • 9.7.1. Company overview
    • 9.7.2. Company snapshot
    • 9.7.3. Operating business segments
    • 9.7.4. Business performance
    • 9.7.5. Key strategies and developments
  • 9.8. Pfizer, Inc.
    • 9.8.1. Company overview
    • 9.8.2. Company snapshot
    • 9.8.3. Operating business segments
    • 9.8.4. Business performance
    • 9.8.5. Key strategies and developments
  • 9.9. Qiagen N.V.
    • 9.9.1. Company overview
    • 9.9.2. Company snapshot
    • 9.9.3. Key strategy move and development
  • 9.10. Genomic Health, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Company snapshot
    • 9.10.3. Business performance
    • 9.10.4. Key strategies and developments

List of Tables

  • TABLE 1: CONVENTIONAL DIAGNOSTICS VS. DIAGNOSTIC BIOMARKER TECHNIQUES
  • TABLE 2: WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES (2012)
  • TABLE 3: REVENUE GENERATION OF BIOLOGICAL AND TARGETED DRUGS IN 2013 ($MILLION)
  • TABLE 4: KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES
  • TABLE 5: COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGS
  • TABLE 6: PATENTS REGISTERED/APPROVED IN THE U.S., EUROPE, CANADA, CHINA, JAPAN, AND OTHERS, 2013 THROUGH 2016
  • TABLE 7: U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
  • TABLE 8: EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
  • TABLE 9: CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016
  • TABLE 10: CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010-2016
  • TABLE 11: JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
  • TABLE 12: OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
  • TABLE 13: CLINICAL TRIALS: CANCER BIOMARKERS
  • TABLE 14: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
  • TABLE 15: WORLD OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 16: WORLD OMICS TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 17: GLOBAL GENOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 1 : LOBAL PROTEOMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 2 : LOBAL OTHER OMICS TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 3 : LOBAL IMAGING TECHNOLOGY MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 4 : LOBAL IMAGING TECHNOLOGY MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 5 : LOBAL IMMUNOASSAYS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 6 : LOBAL IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 7 : LOBAL CYTOGENETICS-BASED TESTS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 8 : LOBAL CYTOGENETICS-BASED TESTS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 9 : LOBAL CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 10: GLOBAL GENETIC BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 11: GLOBAL PROTEIN BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 12: GLOBAL GLYCO-BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 13: CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
  • TABLE 14: GLOBAL CANCER BIOMARKERS FOR LUNG CANCER, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 15: GLOBAL CANCER BIOMARKERS FOR BREAST CANCER, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 16: GLOBAL CANCER BIOMARKERS FOR COLORECTAL CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 17: GLOBAL CANCER BIOMARKERS FOR PROSTATE CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 18: GLOBAL CANCER BIOMARKERS FOR STOMACH CANCER MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 19: GLOBAL CANCER BIOMARKERS FOR OTHER CANCERS, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 20: CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 21: DIAGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 22: DRUG DISCOVERY AND DEVELOPMENT MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 23: PROGNOSTICS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 24: RISK ASSESSMENT MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 25: OTHERS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
  • TABLE 26: CANCER BIOMARKERS MARKET, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 27: NORTH AMERICA CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
  • TABLE 28: NORTH AMERICA CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 29: NORTH AMERICA CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
  • TABLE 30: NORTH AMERICA CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
  • TABLE 31: NORTH AMERICAN CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 32: EUROPEAN CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
  • TABLE 33: EUROPEAN CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 34: EUROPEAN CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
  • TABLE 35: EUROPEAN CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
  • TABLE 36: EUROPEAN CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 37: ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
  • TABLE 38: ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 39: ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
  • TABLE 40: ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
  • TABLE 41: ASIA-PACIFIC CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 42: LAMEA CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022 ($MILLION)
  • TABLE 43: LAMEA CANCER BIOMARKERS MARKET, BY TYPE, 2014-2022 ($MILLION)
  • TABLE 44: LAMEA CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022 ($MILLION)
  • TABLE 45: LAMEA CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022 ($MILLION)
  • TABLE 46: LAMEA CANCER BIOMARKERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
  • TABLE 47: ROCHE: COMPANY SNAPSHOT
  • TABLE 48: ABBOTT: COMPANY SNAPSHOT
  • TABLE 49: ABBOTT: OPERATING SEGMENTS
  • TABLE 50: GSK: COMPANY SNAPSHOT
  • TABLE 51: GSK: OPERATING SEGMENTS
  • TABLE 52: NOVARTIS: COMPANY SNAPSHOT
  • TABLE 53: NOVARTIS: OPERATING SEGMENTS
  • TABLE 54: MERCK: COMPANY SNAPSHOT
  • TABLE 55: MERCK: PRODUCT CATEGORIES
  • TABLE 56: BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 57: ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 58: ELI LILLY: OPERATING SEGMENTS
  • TABLE 59: PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 60: PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 61: QIAGEN: COMPANY SNAPSHOT
  • TABLE 62: GENOMIC HEALTH: COMPANY SNAPSHOT

List of Figures

  • FIG. 1: CANCER BIOMARKERS MARKET: SEGMENTATION
  • FIG. 2: TOP IMPACTING FACTORS: CANCER BIOMARKERS MARKET, 2015-2022
  • FIG. 3: PERCENTAGE (%) OF NEW CANCERS CASES DIAGNOSED IN 2012
  • FIG. 4: TOP INVESTMENT POCKETS: CANCER BIOMARKERS, 2015-2022
  • FIG. 5: TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION
  • FIG. 6: TOP WINNING STRATEGIES: NATURE & TYPE
  • FIG. 7: TYPES OF STRATEGIES DISTRIBUTION
  • FIG. 8: DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
  • FIG. 9: DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
  • FIG. 10: PORTERS FIVE FORCES ANALYSIS
  • FIG. 11: TOP PLAYER POSITIONING, 2015
  • FIG. 12: PATENTS REGISTERED/APPROVED IN THE WORLD, 2013-2016
  • FIG. 13: U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
  • FIG. 14: EUROPE: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
  • FIG. 15: CHINA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
  • FIG. 16: CANADA: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
  • FIG. 17: JAPAN: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
  • FIG. 18: OTHERS: PATENT ANALYSIS BY MARKET PARTICIPANT, 2013-2016
  • FIG. 19: U.S.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 20: CANADA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 21: MEXICO: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 22: GERMANY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 23: U.K.: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 24: FRANCE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 25: ITALY: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 26: RUSSIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 27: REST OF EUROPE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 28: JAPAN: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 29: CHINA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 30: INDIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 31: AUSTRALIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 32: REST OF ASIA-PACIFIC: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 33: BRAZIL: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 34: SAUDI ARABIA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 35: UAE: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 36: REST OF LAMEA: CANCER BIOMARKERS MARKET SIZE, 2014-2022 ($MILLION)
  • FIG. 37: ROCHE: NET SALES, 2013-2015 ($MILLION)
  • FIG. 38: ROCHE: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 39: ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 40: ROCHE: STRATEGY SHARE, 2014-2016 (%)
  • FIG. 41: ABBOTT: NET SALES, 2013-2015 ($MILLION)
  • FIG. 42: ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
  • FIG. 43: ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
  • FIG. 44: ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 45: ABBOTT: STRATEGY SHARE, 2014-2016 (%)
  • FIG. 46: GSK: NET SALES, 2013-2015 ($MILLION)
  • FIG. 47: GSK: REVENUE, BY SEGMENT, 2015 (%)
  • FIG. 48: GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 49: GSK: STRATEGY SHARE, 2014-2016 (%)
  • FIG. 50: NOVARTIS: REVENUE, 2013-2015 ($MILLION)
  • FIG. 51: NOVARTIS: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
  • FIG. 52: NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 53: NOVARTIS: STRATEGY SHARE, 2014-2016 (%)
  • FIG. 54: MERCK: NET SALES, 2013-2015 ($MILLION)
  • FIG. 55: MERCK: REVENUE, BY BUSINESS SEGMENT, 2015 (%)
  • FIG. 56: MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 57: MERCK: STRATEGY SHARE, 2014-2016 (%)
  • FIG. 58: BRISTOL-MYERS SQUIBB: NET SALES, 2013-2015 ($MILLION)
  • FIG. 59: BRISTOL-MYERS SQUIBB, REVENUE, BY GEOGRAPHY, 2015(%)
  • FIG. 60: BRISTOL-MYERS SQUIBB: STRATEGY SHARE, 2014-2016 (%)
  • FIG. 61: ELI LILLY: NET SALES, 2013-2015, ($MILLION)
  • FIG. 62: ELI LILLY: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 63: ELI LILLY: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 64: ELI LILLY: STRATEGY SHARE, 2014-2016 (%)
  • FIG. 65: PFIZER, INC.: NET SALES, 2013-2015, ($MILLION)
  • FIG. 66: PFIZER, INC.: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 67: PFIZER, INC.: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 68: PFIZER, INC.: STRATEGY SHARE, 2014-2016 (%)
  • FIG. 69: QIAGEN: NET SALES, 2013-2015, ($MILLION)
  • FIG. 70: QIAGEN: REVENUE, BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 71: QIAGEN: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 72: QIAGEN: STRATEGY SHARE, 2014-2016 (%)
  • FIG. 73: GENOMIC HEALTH: NET SALES, 2013-2015 ($MILLION)
  • FIG. 74: GENOMIC HEALTH: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIG. 75: GENOMIC HEALTH: STRATEGY SHARE, 2014-2016 (%)
Back to Top